ClinicalTrials.Veeva

Menu
Tasman Health Care | Oncology Research logo

Tasman Health Care | Oncology Research

Research site

Site insights

Top conditions

Top treatments

Darolutamide
Pembrolizumab
ERAS-254
IGM-8444
Xofigo
Androgen
Radium-223 Dichloride
Aplitibart
Naporafenib
Trametinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

5 of 7 total trials

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.Stage 2: To compare progression free survival (PFS) and over...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcin...

Active, not recruiting
HNSCC
NSCLC
Drug: Eftilagimod alpha
Drug: Pembrolizumab

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Active, not recruiting
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Drug: NAH therapy
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart...

Active, not recruiting
Solid Tumor
Chondrosarcoma
Drug: Docetaxel
Drug: Aplitabart (IGM-8444)

Trial sponsors

Bayer logo
AbbVie logo
E
IGM Biosciences logo
I
Nektar Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems